ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Shire's Takhzyro scores EU approval in rare genetic disorder hereditary angioedema
December 04, 2018Shire has announced that it has secured European approval for its subcutaneous injection Takhzyro (lanadelumab) for the routine prevention of attacks as a result of hereditary angioedema (HAE)... -
Shire receives USFDA nod for TAKHZYRO
August 28, 2018TAKHZYRO is the only monoclonal antibody (mAb) that provides targeted inhibition of plasma kallikrein, an enzyme which is chronically uncontrolled in people with hereditary angioedema, to help prevent attacks -
Shire eyes blockbuster sales with 'best-in-class' HAE drug Takhzyro
August 27, 2018Jefferies analyst David Steinberg predicts Shire's Takhzyro could hit $1.8 billion in peak sales.
Pharma Sources Insight January 2025
